ArticleOncoimmunology2023
Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy.
Christoforos K Vaxevanis et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this papercites it
ArticleOncoimmunology2023
Christoforos K Vaxevanis et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.